Related Experiment Video
Updated: Feb 25, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
Manfred Westphal1, Cecile L Maire2, Katrin Lamszus2
1Department of Neurosurgery, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. westphal@uke.de.
Abstract:
The receptor for epidermal growth factor (EGFR) is a prime target for cancer therapy across a broad variety of tumor types. As it is a tyrosine kinase, small molecule tyrosine kinase inhibitors (TKIs) targeting signal transduction, as well as monoclonal antibodies against the EGFR, have been investigated as anti-tumor agents. However, despite the long-known enigmatic EGFR gene amplification and protein overexpression in glioblastoma, the most aggressive intrinsic human brain tumor, the potential of EGFR as a target for this tumor type has been unfulfilled. This review analyses the attempts to use TKIs and monoclonal antibodies against glioblastoma, with special consideration given to immunological approaches, the use of EGFR as a docking molecule for conjugates with toxins, T-cells, oncolytic viruses, exosomes and nanoparticles. Drug delivery issues associated with therapies for intracerebral diseases, with specific emphasis on convection enhanced delivery, are also discussed.
Insights
Epidermal growth factor receptor (EGFR) is a key cancer target, but its potential in glioblastoma remains unfulfilled. This review explores EGFR-targeted therapies and drug delivery for brain tumors.
Area of Science:
- Oncology
- Neuro-oncology
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFR) is a validated target in many cancers.
- EGFR amplification and overexpression are common in glioblastoma, yet therapeutic success is limited.
- Current EGFR-targeted therapies (TKIs, antibodies) show limited efficacy in glioblastoma.
Purpose of the Study:
- To review EGFR-targeted therapeutic strategies for glioblastoma.
- To discuss novel approaches including immunotherapy and drug delivery systems.
- To highlight challenges and future directions for EGFR-targeting in brain tumors.
Main Methods:
- Literature review of EGFR-targeted therapies in glioblastoma.
- Analysis of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies.
- Exploration of immunological approaches, toxin conjugates, and nanocarriers.
- Discussion of drug delivery challenges, including convection-enhanced delivery.
Main Results:
- Despite EGFR amplification in glioblastoma, clinical success of TKIs and antibodies has been limited.
- Various novel strategies are being investigated to overcome therapeutic resistance.
- Drug delivery to the brain remains a significant hurdle for effective treatment.
Conclusions:
- EGFR remains a promising but challenging target for glioblastoma.
- Innovative therapeutic strategies and advanced drug delivery are crucial for clinical translation.
- Further research is needed to fully exploit EGFR's potential in treating this aggressive brain tumor.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...